Life Sciences

  A little over a year ago, I wrote about AstraZeneca’s road to becoming a digital transformation leader. With CIO David Smoley at the helm, the pharmaceutical giant is known to have been an early adopter of many cloud solutions, including Box, Salesforce, and Microsoft Office 365. While Smoley’s cloud-first mentality has helped save a […]

  When site personnel hear that their sponsors have switched to RBM and will no longer be sending monitors at regular intervals throughout the study, they might feel like they’ve been abandoned and that now the burden of executing the study perfectly is 100% on them. Au contraire, my friends! In an RBM strategy, sites […]

  Key findings in a new Gartner report showed that cloud computing is likely to grow 16.5% in 2016, reaching $204 billion in spending. According to Sid Nag, director, cloud technologies at Gartner Research, “The market for public cloud services is continuing to demonstrate high rates of growth across all markets and Gartner expects this […]

  If there’s a time for pharmaceutical and medical device companies to seek more real world data as evidence to support their medical products, that time is now. Real world data, which is the data generated in settings such as routine doctor visits and hospital stays, is often found in electronic health records (EHR) and […]

  While it’s true that both terms include “monitoring,” it’s not true that they’re synonymous. In fact, remote monitoring is actually a subset of risk-based monitoring – a type or form of monitoring, rather than a monitoring strategy, like RBM. 

  If you’ve been waiting to implement Argus Safety 8.x or upgrade your existing environment, the wait is finally over. While the new version was released last year, it takes several months to build a comprehensive validation suite, and I’m happy to announce that Perficient’s life sciences group has completed that task. On top of […]

  Data privacy across all industries continues to be a big concern for everyone. When it comes to the life sciences and healthcare industries, patients are especially worried. They simply are afraid of being identified. In a recent Scientific American article, Adam Tanner discussed the business of buying and selling health data. Health data brokerages […]

  It’s fair, or rather unfair, to say that most of us are affected directly or indirectly by cancer. While oncology treatments continue to be developed at a pace that many therapeutic areas would be envious of, we still have a long way to go. According to the FDA, in 2015, 18 drugs related to […]

  Following an 18-month-long investigation by the United States Senate Committee on Finance, Gilead’s pricing and marketing strategy for its hepatitis drugs, Sovaldi and Harvoni, was deemed one that chooses profit over patient access. In order to appropriately shape policy related to these findings, the Committee has written a letter to the healthcare and patient […]

  Just hearing the word “risk” can make people feel anxious, so it’s natural that the term “risk-based monitoring” conjures up concern. But, in reality, RBM is actually about mitigating risk in clinical trials. 

  If you’re familiar with our blog, you’ll know that we talk a lot about digital transformation; specifically, how life sciences organizations are leveraging digital technology to support their programs. 

  If you’re in the market for a clinical trial management system (CTMS), here’s a Top 10 countdown of reasons why you should choose ASCEND.